2019 Novel Coronavirus Clinical Trial
Official title:
A Pilot, Randomized, Open-label Trial to Determine the Feasibility, Safety, Efficacy, and Pharmacokinetics of Nebulized HCQ01for the Treatment of Patients With COVID-19
This is a pilot, randomized, single-center, parallel group, open-label controlled study to evaluate the feasibility, safety, efficacy, and pharmacokinetics of nebulized HCQ01 plus Standard of Care (SOC) versus SOC alone in hospitalized COVID-19 patients. The Jordanian Ministry of Health (MOH) is the study sponsor, and the study will be conducted at MOH COVID-19 hospitals. Approximately 110 patients, ≥18 years of age with a confirmed SARS-CoV-2 infection, will be enrolled and randomized 1:1 to the treatment and control arms where they will receive ten doses of Hydroxychloroquine solution via nebulizer in addition to SOC or the control arm where treatment will follow the MOH SOC.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04731051 -
The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients
|
Phase 1/Phase 2 | |
| Suspended |
NCT04334967 -
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
|
Phase 4 | |
| Not yet recruiting |
NCT04246242 -
A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)
|
Phase 4 |